Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Signs Three New Customers for Gateway Tech, Clones

NEW YORK, Sept. 30 (GenomeWeb News) - Invitrogen yesterday said it will supply Gateway technology and clones to three genomic research centers in the United States, Germany, and the United Kingdom.

Terms of the licensing agreements call for the company to offer the platform to Open Biosystems, a US-based distributor of genomic and proteomic research products; the UK Medical Research Council, a UK government-funded medical-research organization; and Ressourcenzentrum fur Genomforschung, a nonprofit German service center for genomics and proteomics research.

 

Invitrogen's Gateway technology enables researchers to insert a single entry clone into as many expression vectors as needed to study its function in a variety of ways, according to a company statement.

 

Invitrogen said additional licensing agreements will be announced in the coming weeks. Financial terms of the agreements were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.